What is the history of Phenylketonuria?

Phenylketonuria (PKU) was first identified in 1934 by Norwegian physician Ivar Asbjørn Følling, who discovered that elevated levels of phenylalanine caused intellectual disability. Since that landmark discovery, the medical community has transformed Phenylketonuria from a condition with no known treatment to one effectively managed through lifelong dietary therapy and newborn screening programs.

Who first discovered Phenylketonuria?

The history of Phenylketonuria began in 1934 when Dr. Ivar Asbjørn Følling, a physician and biochemist, examined two children with intellectual disabilities. He noticed a peculiar, musty odor in their urine and, through meticulous chemical analysis, identified the presence of phenylpyruvic acid. This discovery marked the first time a specific metabolic defect was linked to intellectual impairment, establishing Phenylketonuria as a distinct clinical entity initially known as Følling’s disease.

How did our understanding of Phenylketonuria evolve?

In the mid-20th century, researchers identified that Phenylketonuria is an autosomal recessive disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH). This discovery allowed for a deeper understanding of how the body fails to break down the amino acid phenylalanine, which then accumulates in the blood and becomes toxic to the brain. This shifted the view of Phenylketonuria from a mysterious syndrome to a manageable, albeit chronic, metabolic condition.

What were the major milestones in the treatment of Phenylketonuria?

The treatment landscape for Phenylketonuria changed forever in the 1950s when Dr. Horst Bickel developed a low-phenylalanine diet. This proved that dietary intervention could prevent the severe cognitive impacts of the disease. Following this, the 1960s brought the development of the Guthrie test, a simple blood screening method that revolutionized public health.

• 1934: Dr. Ivar Følling identifies phenylpyruvic acid in the urine of patients.


• 1953: Dr. Horst Bickel demonstrates the efficacy of a low-phenylalanine diet.


• 1963: Robert Guthrie introduces the bacterial inhibition assay, enabling universal newborn screening.


• 2007: FDA approval of sapropterin dihydrochloride (Kuvan), a pharmacological treatment for specific patients.


• 2018: FDA approval of pegvaliase-pqpz (Palynziq), an enzyme substitution therapy for adults.

How has patient advocacy shaped the modern experience of Phenylketonuria?

The patient advocacy movement has been critical in normalizing the lives of those with Phenylketonuria. Early misconceptions—such as the belief that patients could stop their diet after childhood—were corrected through the tireless work of families and clinicians who pushed for "diet for life" protocols. Today, the DiseaseMaps.org community, which includes 381 members living with Phenylketonuria, continues this tradition by sharing lived experiences and advocating for better access to medical foods and emerging gene therapies.

Next steps

• Consult a metabolic specialist or geneticist to stay updated on the latest clinical management guidelines.


• Join a patient support group or the Phenylketonuria community on DiseaseMaps.org to connect with others sharing similar health journeys.


• Discuss with your care team whether you are a candidate for newer pharmacological therapies or clinical trials.


• Ensure you have access to a registered dietitian who specializes in metabolic disorders.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD): Phenylketonuria.


• Orphanet: Phenylketonuria (ORPHA:71).


• Online Mendelian Inheritance in Man (OMIM): Phenylketonuria; PKU (Entry #261600).


• National PKU Alliance (NPKUA): History and Clinical Guidelines.